# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABOUT SIOG</td>
<td>3</td>
</tr>
<tr>
<td>Mission &amp; Vision</td>
<td>3</td>
</tr>
<tr>
<td>1. Education</td>
<td>3</td>
</tr>
<tr>
<td>2. Clinical practice</td>
<td>3</td>
</tr>
<tr>
<td>3. Research</td>
<td>3</td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAMME COMMITTEE</td>
<td>4</td>
</tr>
<tr>
<td>WELCOME MESSAGE</td>
<td>5</td>
</tr>
<tr>
<td>SIOG supporting Global Policy for Cancer in the Ageing – Webinar</td>
<td>6</td>
</tr>
<tr>
<td>Address Note</td>
<td>6</td>
</tr>
<tr>
<td>Programme</td>
<td>7</td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAMME</td>
<td>9</td>
</tr>
<tr>
<td>SCIENTIFIC POSTERS LIST*</td>
<td>11</td>
</tr>
<tr>
<td>SPONSORS</td>
<td>12</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENT</td>
<td>13</td>
</tr>
</tbody>
</table>
ABOUT SIOG

The International Society of Geriatric Oncology, also called SIOG (Société Internationale d’Oncologie Gériatrique) in French, is a multidisciplinary membership-based society with members engaged in more than 80 countries around the world. Our network includes geriatricians, medical oncologists, surgical oncologists, radiation oncologists, anaesthesiologists, nurses and allied health professionals. Founded in 2000, SIOG was officially registered as a not-for-profit organisation under the Swiss law in October 2012. Ever since, SIOG has established a long-standing history of implementing programmatic activities in the field of Geriatric Oncology via 3 strategic directions: education, clinical practice and research.

Powered by global collaborations, the SIOG network is committed to strengthening the national capacity for Human Resources for Health (HRH) in various countries and in promoting and advocating for the health agenda of the Sustainable Development Goal (SDG3) i.e. ‘Ensure healthy lives and promote wellbeing for all at all ages’.

Mission & Vision

The goal of SIOG is to strengthen the capacity of health professionals in the field of geriatric oncology, in order to optimise treatment of older adults with cancer. SIOG operates via 3 strategic directions:

1. Education

- Disseminate knowledge in order to maintain a high common standard of healthcare in older cancer patients
- Integrate geriatric oncology in the curricula for medical and nursing education to ensure a high standard of qualification for healthcare professionals
- Address the shortage of specialist oncologists/geriatricians & allied health staff in geriatric oncology
- Increase public awareness of the worldwide cancer in the elderly epidemic

2. Clinical practice

- Integrate geriatric evaluation (including comorbidities) into oncology decision-making and guidelines
- Improve the quality of prevention, diagnosis, treatment, and follow-up of older patients with malignancies
- Address issues of access to care, including the needs of the caregiver
- Develop interdisciplinary geriatric oncology clinics

3. Research

- Develop, test and disseminate easy screening tools
- Create a clear and operational definition of vulnerability/frailty applicable to oncology
- Increase the relevance of clinical trials for older patients
- Improve research in the field of geriatric oncology
- Promote multidisciplinary, basic/translational research on the interface of ageing and cancer
SCIENTIFIC PROGRAMME COMMITTEE

Holly Holmes, USA
Kwok-Leung Cheung, UK
Nicolo Matteo Luca Battisti, UK
Raúl Córdoba Mascuñano, Spain
Nienke de Glas, The Netherlands
Theodora Karnakis, Brazil
Melissa Loh, USA
Isacco Montroni, Italy
Lucinda Morris, Australia
Martine Puts, Canada
Hans Wildiers, Belgium
The coronavirus pandemic has dramatically affected health care professionals and patients worldwide. This is a very unsettling time for everyone and everywhere. In light of the current circumstances and in abundance of caution, travel and attendance could not return to normal by the time of the 2020 SIOG Annual Conference.

The SIOG 2020 Annual Meeting Online will ensure that the geriatric oncology community continues to connect and collaborate, in times when live attendance is not possible due this serious global health challenge. The pandemic has impacted the treatment and care of our older patients. Join SIOG 2020 and contribute.

We look forward to seeing you at this meeting and hope that you will enjoy the benefits of the remote session to the fullest.

Kind greetings,

Dr Holly Holmes and Prof KL Cheung
Co-chairs,
SIOG 2020 Annual Meeting Online
The International Society of Geriatric Oncology (SIOG) has organised a webinar on the Impact of COVID-19 on older adults with cancer. SIOG is pleased to have the World Health Organisation fully represented. Public health leaders, speakers from Governments, Ministries of Health and Institutions will join the conversation.

The COVID-19 pandemic poses a barrier to equal and evidence-based management of cancer in older adults. The International Society of Geriatric Oncology (SIOG) formed a panel of experts to develop consensus recommendations on the implications of the pandemic on several aspects of cancer care in this age group including geriatric assessment (GA), surgery, radiotherapy, systemic treatment, palliative care and research.

Age and cancer diagnosis are significant predictors of adverse outcomes of the COVID-19 infection. Ongoing research is necessary to expand knowledge of the management of cancer in older adults. However, the pandemic presents a significant barrier and efforts should be made to ensure equitable access to clinical trials and prospective data collection to elucidate the outcomes of COVID-19 in this population.

Dr Nicolò Luca Mateo Battisti and Dr Anna Mislang

Co-chairs,
SIOG COVID-19 Working Group
Programme

Date/time: 30th September 2020 / 14:00 (CEST)

1. **Introductory session**
   - **Welcome Remarks**
     Partnerships for global health research on COVID-19 affecting Older People with Cancer,
     *Meena Cherian, Senior Advisor - Global Action, SIOG*
   - SIOG advocating policies for promoting equity during COVID-19 affecting older people
     with Cancer, *Anna Mislang, SIOG COVID-19 Working Group Co-Chair*
   - SIOG guidelines on cancer in older people, *Hans Wildiers, SIOG President*

2. **Plenary session**
   **Chair: Meena Cherian**
   - **Patients/Community Perspective**
     Jan Geissler, Founder and CEO, Patvocates, Germany

   **Enhancing collaborations for supporting capacity building at country level**
   - **WHO Headquarters, Geneva Switzerland**
     1. Andre Ilbawi - WHO Department for Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention (NVI)
     2. Yuka Sumi – Medical officer at WHO HQ Geneva, Switzerland
   - **WHO regions/countries**
     1. WHO AFRO - Prebo Barango, Medical officer NCD, Intercountry Support team for East and Southern Africa
     2. WHO/PAHO - Erica Wheeler, Sub regional Advisor on Human Resources for Health
     3. WHO Country Office for India - Atreyi Ganguli, National Professional Officer
   - **Governments/MOH**
     1. Philippines - Clarito U. Cairo, Jr, Deputy of Health, National Integrated Cancer Control including Palliative and Hospice Care and Thyroid Disorders
     2. Iran - Reza Assadi, School of Medicine, Mashhad University of Medical Sciences
     3. Egypt - Hussein Khaled, Professor Medical Oncology at National Cancer Institute of Cairo University
   - **Institutions**
     1. Martine Extermann, Moffitt Cancer Center, Tampa FL, USA
     2. Enrique Soto, ASCO (*American Society of Clinical Oncology*)
     3. Matti Aapro, European *Cancer* Organisation
     4. Antonella Cardone, Director of European Cancer Patient Coalition

3. **Participants Questions and Discussions**
   **Chair: Nicolò Battisti & SIOG National Representatives**
   Armin Shahrokni US; KL Cheung, UK; Enrique Soto, Mexico; Yervand Hakobyan, Armenia; Regina Gironés, Spain; Barbara van Leeuwen, Netherlands; Heather Lane, Australia; Anne Horgan, Ireland; Reinhard Stauder, Austria; Martine Puts, Canada

4. **Concluding Remarks on the way forward for SIOG**
1. SIOG support for capacity building (skills, education, digital technology) at country level in collaboration with WHO and NGOs during COVID-19 affecting Older People with Cancer, Etienne Brain, ESMO- SIOG Cancer in the Elderly Working Group
2. Aligning SIOG with WHO recommendations on Cancer in Older people, Ravindran Kanesvaran, SIOG President-elect
SCIENTIFIC PROGRAMME

Date / Time: 01st October 2020 / 15:00 – 18:00 CEST

15:00 – 15:10 Celebration to mark SIOG’s 20th Anniversary
Speakers: Hans Wildiers (BE), Ravindran Kanesvaran (SG)

Chairs: Nicolo Battisti (UK), Anna Mislang (AU)

Geriatrics
Speaker: Lisa Cooper (US)

Surgery
Speaker: Michael Jaklitsch (US)

Radiation Oncology
Speaker: Anita O’Donovan (IRL)

Systemix Tx
Speaker: Anna Mislang (AU)

15:55 – 16:10 Questions & Answers

16:10 – 16:40 Rapid Fire Abstracts

Extreme Hypofractionation Utilizing Stereotactic Body Radiation Therapy is Well Tolerated in Elderly Prostate Cancer Patients
Speaker: Monica A Pernia (US)

Prevalence of geriatric syndromes in community-dwelling elderly cancer survivors
Speaker: Rei Ono (JP)

Feasibility and results of a pragmatic geriatric assessment (PGA) in a Brazilian Oncology unit. A plan to bypass the most common obstacles in implementing geriatric assessment to older patients with cancer
Speaker: Antonio Fabiano Ferreira Filho (BR)

Qualitative study of a mobile health exercise intervention for older patients with myeloid neoplasms
Speaker: Chandrika Sanapala (US)

16:40 – 18:00  Updates in:

- **Hematology**
  Speaker: Tanya Wildes (US)

- **Medical Oncology**
  Speaker: Enrique Soto (MX)

- **Geriatrics**
  Speaker: Siri Rostoft (NO)

- **Radiation Oncology**
  Speaker: Lucinda Morris (AU)

- **Surgical Oncology**
  Speaker: Isacco Montroni (IT)
Geriatric Syndromes and Treatment Toxicities in Older Patients with Malignant Gliomas
Andrea Wasilewski

Dealing with the lack of evidence to treat depression in older patients with cancer: French Societies of Geriatric Oncology (SOFOG) and PsychoOncology (SFFPO) Position Paper based on a systematic review
Berengere Beauplet

Referral to Geriatricians among Uruguayan Haematologists
Gimena dos Santos

Exploring how older patients with advanced hematologic malignancies utilize their social network: A qualitative study
Grace DiGiovanni

Older adults (OA) age 70+ experience similar survival outcomes to younger adults (YA) age <70 receiving 2nd line therapy for metastatic CRC (mCRC): analysis of 5289 patients (pts) from the ARCAD Clinical Trials Program
Nadine J Mccleary

Nutritional Risk status predicts overall survival of Elderly Mexican patients with advanced non-small-cell lung cancer (NSCLC)
Saul Campos Gomez

Geriatric screening and assessment among older patients with cancer: Evaluation of long-term patient outcomes in a multicentric prospective cohort study of almost 12,000 patients
Victoria Depoorter

*To view full poster, please visit SIOG 2020 Annual Meeting Online website*
SIOG gratefully acknowledges contribution of the following companies:

At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries. Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology. Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do.

Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on developing therapies in oncology, rare diseases, rare blood disorders, multiple sclerosis, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. In oncology, we are building on a rich legacy with a strong pipeline and a continued commitment to contribute meaningful solutions for patients with cancer. Through rigorous drug discovery and development rooted in cutting-edge science and innovative technologies, we are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.
ACKNOWLEDGEMENT

We wish to thank SIOG members for all their cooperation and support in hosting this virtual event in the context of the COVID-19 pandemic.

We also wish to extend our gratitude to the representatives of the World Health Organisation and all the panellists for their contribution in the SIOG COVID-19 Webinar.

Special acknowledgement to the members of our Scientific Programme Committee and the speakers for their crucial work of designing the content and the structure of the programme.

We also thank all our corporate financial donors and sponsors and look forward to a lasting partnership.

Thank you to everyone for helping us deliver a successful SIOG 2020 Annual Meeting Online.

SIOG Head Office